| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 195.53 | 9.7% | 17.9% |
| Total Income | 200.51 | 8.7% | 18.0% |
| Expenditure | 159.24 | 1.3% | 12.3% |
| PBT | 35.11 | 43.6% | 25.0% |
| Net Profit | 28.05 | 41.3% | 47.9% |
| OPM | 26.43% | 6.52pp | 22.56pp |
| NPM | 13.99% | 7.78pp | 2.74pp |
| EPS | 1.82 | 79.9% | 49.2% |
Thyrocare Technologies Reports Q3FY26 Revenue of INR 195.53 Cr with 18% YoY Growth
28 Jan 2026 · 28 Jan, 4:32 pm
Summary
Thyrocare Technologies Limited, a leading healthcare diagnostics company, has announced its results for the quarter ended December 31, 2025. The company reported a revenue of INR 195.53 Cr with a year-on-year growth of 18%. The Pathology business, which is the primary revenue driver, saw a 20% increase. The company processed 49.6 million tests in Q3FY26, marking a 22% year-on-year growth. Consolidated EBITDA grew by 38% year-on-year, and Profit After Tax (PAT) grew by 47% year-on-year to Rs 27.91Cr.
Key Highlights
- 1
Thyrocare awarded as National diagnostic champion of the year
- 2
Best Diagnostic Lab Chain of the Year and Patient-Centric Diagnostic Company of the Year awards
- 3
Madhuri Dixit onboarded as Thyrocare Brand Ambassador
- 4
49.6 million tests processed in Q3FY26 with a 22% year-on-year growth
- 5
Consolidated revenue registered a 18% year-on-year growth
- 6
Consolidated EBITDA grew by 38% year-on-year
- 7
Profit After Tax (PAT) grew by 47% year-on-year
Management Comments
Rahul Guha
MD & CEO, Thyrocare Technologies Ltd
We are pleased to report a robust set of results for the quarter. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India
Informational and educational content only. Not investment advice.